The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective - Neurological Edition

  • ID: 4606134
  • Report
  • PatientView
1 of 5
Patient Groups Specialising in Neurological Conditions Hold Diverse Views about Pharma's Corporate Reputation (and How the Industry Could Improve)

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Biogen
  • Eisai
  • Janssen
  • Novartis
  • MORE
  • The views of 202 neurological patient groups - with a focus on patient groups specialising in epilepsy, multiple sclerosis, and Parkinson's disease.
  • Drawn from a November 2017-February 2018 survey.

State of relationships between neurological patient groups and the pharmaceutical industry

The 202 neurological patient groups worldwide responding to the 2017 survey on the ‘Corporate Reputation of the Pharmaceutical Industry’ were more positive about the industry’s corporate reputation than their predecessors in 2016.  42% of 2017's respondent neurological patient groups stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation - ranking the industry 3rd for corporate reputation out of nine healthcare sectors (compared with the equivalent 2016 figure of 28%, which ranked pharma 5th out of eight healthcare sectors in 2016).

One possible explanation for the industry’s rise in corporate reputation among neurological patient groups in 2017 could be that the levels, or the quality (or both), of industry partnerships with neurological patient groups increased that year. In 2017, 40% of the neurological patient groups described pharma as “Excellent” or “Good” at patient-group partnerships, compared with 28% in 2016.

Views of neurological patient groups vary

The one major theme running through this neurological analysis, however, is the significant diversity in attitude between the neurological patient organisations - according to their neurological specialty. A chart in the report shows the different perspectives of the various types of neurological patient groups on the overall corporate reputation of the pharma industry for each of the 12 indicators of corporate reputation.

The data show the following:

  • Multiple-sclerosis patient groups seem to be the most positive of the neurological patient groups about the performance of pharmaceutical companies at a number of indicators of corporate reputation, including: patient information; the provision of high-quality products; and patient-group partnerships. However, MS patient groups are less convinced of pharma’s corporate reputation in the area of patient safety.
  • Epilepsy patient groups are, on average, more satisfied than most types of neurological patient groups with pharma companies across all 12 measures of corporate reputation. However, they are less satisfied with industry’s delivery of high-quality products. The feedback received by the 2017 survey from these epilepsy patient groups refer, in particular, to problems of access to medicines.
  • Patient groups specialising in Parkinson’s disease have varying attitudes across the 12 indicators of corporate reputation. These patient groups are most positive about the quality of companies’ patient-group relationships, but least positive about industry’s transparency.

The purpose of considering 2017’s neurological Corporate-Reputation results in such detail is to highlight the fact that not all neurological patient groups hold similar views on pharmaceutical companies - and, therefore, not all of these patient groups have similar needs.

How pharma could improve: comments from four very-different neurological patient groups...

Canadian local epilepsy patient group requesting more investment in research, and improvements in access to medicines.

"More clinical trials. Provide funding for new medications not covered by the Ontario Health Insurance Plan (OHIP), or by Ontario Works (OW).”

Spanish regional multiple-sclerosis patient group commenting on the need for improved patient-group relationships, with the aim of improving communication between industry and patient groups.

“Trabajar en equipo con las Entidades de pacientes, más reuniones, más comunicación y menos protocolos y documentación.” [“Work as a team with patient organisations - more meetings, more communication, and fewer protocols and documentation.”

UK national neurological patient group discussing Parkinson's disease and offering evidence that pharma could benefit from improving its understanding of patients' needs.

“From a survey we did recently, only 27% of people affected by Parkinson’s said that they thought the pharmaceutical industry understood the needs of people with Parkinson’s. 64% said they didn’t know.”

US national dementia patient group expressing frustration with slow progress being made in R&D.

“Many of our members appreciate all that pharmaceutical companies are doing to develop new, and better, therapies to address dementia. But—frustration is high about disappointing trial results, and uncertainty about when progress for patients will be more tangible.”

So, how did the companies perform at corporate reputation in 2017, in the viewpoints of patient groups Specialising in neurological conditions?

Ranking at corporate reputation is measured by patient groups familiar with a company.

  • UCB was ranked overall 1st out of 27 companies for corporate reputation in 2017 (as it had been in 2016 and 2015) by the 49 respondent neurological patient groups familiar with it.
  • Lundbeck was ranked overall 2nd out of 27 companies for corporate reputation in 2017 by the 59 neurological patient groups familiar with it.
  • Eisai was ranked overall 3rd out of 27 companies for corporate reputation in 2017 by the 41 neurological patient groups familiar with it (an improvement on its 2016 performance of 9th out of 21 companies).

Given the varied opinions of neurological patient groups, it is hardly surprising that epilepsy, multiple-sclerosis, and Parkinson’s patient groups have different reactions to individual pharmaceutical companies. Thus:

  • Eisai was ranked overall 1st for corporate reputation in 2017 by the 16 respondent epilepsy patient groups familiar with it (above four other companies: GSK, Novartis, Pfizer, and UCB).
  • Novartis was ranked overall 1st for corporate reputation in 2017 by the 49 respondent multiple-sclerosis patient groups familiar with it (above nine other companies: AstraZeneca, Bayer, Biogen, Janssen, Merck KGaA, Pfizer, Roche/Genentech, Sanofi, and Teva).
  • Lundbeck was ranked overall 1st for corporate reputation in 2017 by the 19 respondent Parkinson's patient groups familiar with it (above four other companies: (AbbVie, Novartis, Pfizer, and Roche/Genentech).
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Biogen
  • Eisai
  • Janssen
  • Novartis
  • MORE

1 Executive Summary
5 Sector Analysis: Epilepsy; Multiple Sclerosis; And Parkinson’s
12 The Relationships That Neurological Patient Groups Have With Pharma, 2017
15 Industry-Wide Findings From Neurological Patient Groups, 2017
19 Rankings Of The 27 Pharma Companies, 2017 V. 2016 Among Neurological Patient Groups Familiar With The Companies
34 Positionings Of 23 Pharma Companies, 2017 V. 2016 Among Neurological Patient Groups That Work/Partner With The Companies
49 Profiles Of The 27 Companies, 2017
 
Appendices
I. Neurological Patient Groups: Their Views On Pharma And Their Recommendations For Improvement
II. Profiles Of The 202 Respondent Neurological Patient Groups, 2017

Tables and Charts
The Views That Neurological Patient Groups Have On The Pharma Industry’S Corporate Reputation, 2013-2017
The Varying Views Of The Different Types Of Neurological Patient Groups On Pharma’s Corporate Reputation, 2017
Companies Ranked First By Neurological Patient Groups For Each Of The 12 Indicators Of Corporate Reputation, 2017
How The Views Of Dementia, Epilepsy, Multiple Sclerosis, And Parkinson’S Patient Groups Vary On The 12 Indicators Of Corporate Reputation—And Compared With The Views Of
Patient Groups From All Therapy Areas, And All Neurological Patient Groups, 2017
The Views Of Neurological Patient Groups On Industry’S Ability In 2017 To (I) Be Patient Centric; And (II) Provide High-Quality Products
The Performance Of Five Companies At The 12 Indicators Of Corporate Reputation-As Assessed By Epilepsy Patient Groups, 2017
The Views Of Neurological Patient Groups On Industry’S Ability In 2017 To (I) Produce Patient Information; And (II) Ensure Patient Safety
The Performance Of 10 Companies At The 12 Indicators Of Corporate Reputation—As Assessed By Multiple-Sclerosis Patient Groups, 2017
The Views Of Neurological Patient Groups On Industry’S Ability In 2017 To (I) Partner With Patient Groups; And (II) Have Integrity
The Performance Of Five Companies At The 12 Indicators Of Corporate Reputation-As Assessed By Parkinson’S Patient Groups, 2017
The Number Of Neurological Patient Groups Familiar, And Partnering, With The 27 Companies, 2017
The Ways In Which Pharmaceutical Companies Help Their Neurological Patient-Group Partners, 2017
The Corporate Reputation Of The Pharmaceutical Industry, 2017 V. 2016—Compared With
That Of Eight Other Healthcare Sectors, According To Neurological Patient Groups
Neurological Patient Groups On The Pharmaceutical Industry’S Efficacy At The Indicators Of Corporate Reputation, 2017—Chart And Table
Neurological Patient Groups On The Pharmaceutical Industry’S Efficacy At The Indicators Of Corporate Reputation 2017 V. 2016, V. Patient Groups Of All Therapy Areas 2017
Rankings Of 27 Individual Pharma Companies, 2017 V. 2016 (According To Neurological Patient Groups Familiar With The Company)
Positionings Of Five Individual Pharma Companies, 2017 V. 2016 (According To Neurological
Patient Groups That Work/Partner With The Company)
Profiles Of The 27 Companies, 2017

Charts and Tables:

  • Number Of Neurological Patient Groups Claiming Familiarity With The Company, 2017.
  • Number Of Neurological Patient Groups Saying That They Had A Working Relationship With The Company, 2017.
  • Company Performance Scores Among Neurological Patient Groups Familiar With The Company,
  • And Which Worked With The Company, For Each Of The 12 Indicators Of Corporate Reputation, 2017.
  • Percentage Of The Neurological Patient Groups That Worked With The Company, But Which Also Worked With Other Companies, 2017.
  • Profile Of Respondent Neurological Patient Groups Familiar With The Company, 2017: Country
  • Headquarters; Geographic Remit; And The Ways In Which The Company Helps The Neurological
  • Patient Groups That Partner With It.
  • The Company’S Pcris (Patient Corporate Reputation Index) For Each Of The 12 Indicators—As Assessed By Neurological Patient Groups Familiar With The Company, 2017 V. 2016 V. 2015.
  • Overall Rankings For The Company—According To Neurological Patient Groups Familiar With The Company, 2017.
  • Overall Positionings For The Company—According To Neurological Patient Groups That Work With The Company, 2017.
  • Company Rankings For Each Of The 12 Indicators—According To Neurological Patient Groups Familiar, Or Working, With The Company, 2017 V. 2016.

The 27 Companies
Abbvie
Acorda
Allergan
Almirall
Amgen
Astellas
Astrazeneca
Bayer
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Eisai
Eli Lilly
Grünenthal
Gsk
Janssen
Lundbeck
Merck & Co/MSD
Merck Kgaa
Novartis
Pfizer
Roche (Genentech In The US)
Sanofi
Takeda
Teva
UCB

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  •  AbbVie
  •  Acorda
  •  Allergan
  •  Almirall
  •  Amgen
  •  Astellas Pharma
  •  AstraZeneca
  •  Bayer
  •  Biogen
  •  Boehringer Ingelheim
  •  Bristol-Myers Squibb
  •  Celgene
  •  Eisai
  •  Eli Lilly
  •  Grünenthal
  •  GSK
  •  Janssen
  •  Lundbeck
  •  Merck & Co/MSD
  •  Merck KGaA
  •  Novartis
  •  Pfizer
  •  Roche/Genentech
  •  Sanofi
  •  Takeda
  •  Teva
  •  UCB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll